Replimune Group, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biotechnology company developing oncolytic immunotherapies RP1, RP2 and RP3. This fiscal second-quarter filing covers the three and six months ended September 30, 2020; comparisons are to the same 2019 periods. The interim financial statements are unaudited. Replimune had no approved products and generated no product-sales revenue.
Financial performance and position
| Metric | Quarter ended Sept. 30, 2020 | Prior-year quarter | Six months ended Sept. 30, 2020 | Prior-year six months |
|---|---|---|---|---|
| Revenue from product sales | $0 | $0 | $0 | $0 |
| Research and development expense | $14.1m | $8.2m | $26.2m | $15.6m |
| General and administrative expense | $5.6m | $4.1m | $11.3m | $7.5m |
| Operating loss | $19.7m | $12.2m | $37.5m | $23.1m |
| Net loss | $20.1m | $11.1m | $37.6m | $20.6m |
| Net loss per share, basic and diluted | $0.46 | $0.35 | $0.90 | $0.65 |
At September 30, cash and cash equivalents were $43.3m and short-term investments were $201.3m, totaling $244.6m; restricted cash was an additional $1.6m. Total assets were $314.2m, total liabilities $52.9m, and stockholders’ equity $261.4m. Long-term debt was $10.0m principal ($9.8m net of discount); finance-lease liabilities were $27.3m. The filing reports no product gross margin; operating margins are not meaningful for this pre-revenue company.
For the six months, operating cash use was $32.3m (versus $33.6m in 2019). Investing activities used $93.9m, chiefly reflecting purchases of short-term investments; financing provided $109.5m, principally from the June equity and pre-funded warrant offering. Replimune reported $37.6m of accumulated deficit and expects continuing losses.
Material changes versus prior comparable periods
- Quarterly R&D expense rose $5.9m year over year, mainly from RP1 clinical-trial and manufacturing-facility costs and increased R&D staffing. Six-month R&D increased $10.6m.
- Quarterly G&A expense rose $1.5m; six-month G&A rose $3.8m, reflecting increased personnel, facilities, insurance and professional fees.
- Net loss widened by $9.0m for the quarter and $16.9m for the six-month period. Higher operating costs and increased lease and debt interest contributed; investment income and other income were lower.
- Cash and investments increased substantially from March 31, reflecting the June offering, while the investment portfolio shifted toward U.S. Treasury and government-agency bonds.
Outlook, commentary, risks and unusual items
- Management said September 30 cash and investments alone were expected to fund operations for at least 12 months from issuance of the financial statements. After the October 2020 offering, management estimated available resources would fund operations into the second half of 2024; this estimate depends on assumptions and spending.
- On October 26, 2020, after quarter-end, the company completed an offering of common shares and pre-funded warrants, reporting approximately $270m net proceeds. This is a subsequent event, not included in September 30 cash.
- RP1 combination-trial data were described as promising but preliminary. The company reported responses in small, early-stage cohorts; the planned primary data readouts for the RP1 Phase 2 CSCC and melanoma studies were expected in 2022. No patients had yet enrolled in the RP1 transplant-recipient CSCC study, with COVID-19 cited as a factor.
- For RP2, nine patients had received single-agent treatment by October 15, 2020: three had confirmed ongoing responses, and no dose-limiting toxicities were reported. Ten patients had entered the combination cohort, with none yet evaluable for efficacy. These are early clinical observations and do not establish efficacy or approval prospects.
- Management intended to initiate a Phase 1 RP3 trial by the end of 2020. COVID-19 could slow trial enrollment, disrupt suppliers or manufacturing, and delay development timelines; effects remained uncertain.
- Key risks include clinical and regulatory failure, dependence on third-party suppliers and collaborators, future financing needs and possible dilution, and the costs and execution risks of the company’s manufacturing facility. Hercules debt is secured by substantially all assets except intellectual property; $30m of additional borrowing capacity was subject to terms and milestones.
- Disclosure controls were deemed ineffective as of September 30 due to material weaknesses involving staffing, segregation of duties, and controls for complex transactions. Remediation was underway but was not considered complete. Management stated the filed financial statements fairly present the company’s position and results.
- No material litigation was reported, and the company disclosed no off-balance-sheet arrangements. The filing reported no material changes in contractual commitments during the six-month period.
Important facts for investors to verify
- Whether the October offering proceeds and the stated second-half-2024 runway remain consistent with actual cash burn, trial spending and manufacturing costs.
- Progress, enrollment and complete follow-up data for RP1 and RP2 trials, including the planned 2022 readouts; distinguish interim company-reported results from controlled, mature clinical evidence.
- COVID-19’s continuing effects on trial enrollment, especially the transplant-recipient study, and on clinical supply and timelines.
- Remediation and testing of internal-control weaknesses, and whether controls become effective in later filings.
- Potential dilution from shares, outstanding pre-funded warrants, stock options and any future ATM or equity issuance; also monitor Hercules borrowing conditions and lease obligations.